大麻合法化并没有减少炎症性肠病患者的阿片类药物处方:差异差异分析
Mohamed Noureldin1, Tony Van2, Shirley Cohen-Mekelburg1,2,3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
The American journal of gastroenterology
|May 20, 2024
概括
大麻合法化并没有减少对炎症性肠病 (IBD) 患者的阿片类药物处方. 在拥有和没有合法大麻的州,阿片类药物的使用同样下降,这表明没有显著的关联.
科学领域:
- 胃肠病学 胃肠病学
- 疼痛管理 疼痛管理
- 公共卫生政策 公共卫生政策
背景情况:
- 炎症性肠病 (IBD) 患者经常经历疼痛,导致阿片类药物使用.
- 大麻被探索为IBD潜在的替代性疼痛管理策略.
研究的目的:
- 调查大麻合法化是否影响IBD患者的阿片类药物处方率.
- 确定州级大麻合法化与IBD中阿片类药物处方趋势之间的关联.
主要方法:
- 对2009-2016年的MarketScan数据进行差异分析.
- 在大麻合法化州和未合法化州的阿片类药物处方率的比较.
主要成果:
- 分析了合法大麻州的6,240名IBD患者和非合法州的79,272名IBD患者.
- 随着时间的推移,阿片类药物处方率在两组中都有所下降.
- 在大麻合法化和未合法化州之间,没有观察到大麻合法化率的显著差异 (P=0.96).
结论:
- 大麻合法化与IBD患者的阿片类药物处方减少无关.
- 对IBD患者的阿片类药物处方趋势反映了各种疾病的国家模式.
- 可能需要进一步的研究来探索大麻在IBD疼痛管理中的作用.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
193
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
193
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Analgesia and Pain Management
582
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
582
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Diarrhea-Predominant IBS
160
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
160


